Related Experiment Video

Updated: Sep 20, 2026

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

PPARgamma and metabolism: insights from the study of human genetic variants

Mark Gurnell1

  • 1Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. mg299@mole.bio.cam.ac.uk

Clinical Endocrinology
|August 16, 2003
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARgamma) influences major diseases like diabetes and obesity. Genetic variations in PPARgamma offer insights into metabolic regulation and potential therapeutic targets.

Area of Science:

  • Molecular biology
  • Metabolic diseases
  • Genetics

Background:

  • Diabetes, obesity, atherosclerosis, and cancer are leading causes of mortality in Western societies.
  • The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is implicated in these pathological processes.
  • Thiazolidinediones, insulin-sensitizing agents for type 2 diabetes, highlight the therapeutic potential of modulating PPARgamma.

Purpose of the Study:

  • To review recent studies on the role of PPARgamma in metabolic processes.
  • To explore the therapeutic implications of PPARgamma modulation in metabolic diseases.
  • To examine the impact of inherited variations in the human PPARgamma gene on metabolism.

Main Methods:

  • Analysis of signaling pathways regulated by PPARgamma using high-affinity ligands.
  • Study of human subjects with naturally occurring mutations and polymorphisms in the PPARgamma receptor.
  • Review of recent scientific literature on PPARgamma's role in metabolism and disease.

Main Results:

  • PPARgamma plays a crucial role in regulating metabolic processes, including glucose homeostasis, lipid metabolism, and fat mass.
  • Genetic variations in PPARgamma provide significant evidence linking the receptor to mammalian metabolic regulation.
  • Modulation of PPARgamma activity shows therapeutic promise for metabolic disorders.

Conclusions:

  • PPARgamma is a pivotal nuclear receptor in regulating mammalian metabolism.
  • Understanding inherited variations in PPARgamma is essential for comprehending its role in metabolic health and disease.
  • Targeting PPARgamma pathways offers potential therapeutic strategies for major metabolic diseases.

More Related Videos

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies14:56

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Published on: May 6, 2022

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...